电子知情同意在药物临床试验中的可行性探讨

蛋白多肽类药物脂质体是将蛋白多肽类药物用脂质体包封后形成的载药脂质体，具有靶向、缓释、良好的稳定性等优点。综述了2000年以来中国专利申请中涉及的新型蛋白多肽类药物脂质体，包括凝胶型脂质体、前体脂质体、长循环脂质体、免疫脂质体、柔性脂质体、pH敏感脂质体、配体修饰脂质体、磁性纳米脂质体、多囊脂质体，为继续开发新型的蛋白多肽类药物脂质体提供新的思路。

Discussion on feasibility of electronic informed consent in drug clinical trials

With the development of science and technology, electronic information technology has penetrated into many aspects of society now. Electronic informed consent is an effective way to adapt to development clinical trial. China is still at an early stage in this field. Affected by the outbreak of COVID-19 in 2020, the demand for electronic informed consent in clinical trial has become more urgent. Based on my own work experience, the author wants to analyze the problems in the traditional informed consent process and the current situations of electronic informed consent in China and explores the feasibility of electronic informed consent in clinical trials.